Non-Small Cell Lung Cancer Treatment Strategies
Clinical research in non-small cell lung cancer spans advanced, metastatic, and locally advanced disease, with attention to treatment selection across first-line, maintenance, and later-line settings.
- PD-L1-positive disease
- Stage III lung cancer
- Relapsed and progressing disease
Research activity includes approaches aimed at improving tumour control and survival in patients with unresectable or recurrent NSCLC.
EGFR-Mutated Lung Cancer
Several studies focus on epidermal growth factor receptor-driven disease, including patients with classical and uncommon activating mutations and those with brain involvement.
- EGFR mutation-positive NSCLC
- Brain metastases
- Therapy sequencing
The research landscape includes treatment strategies for untreated and advanced mutation-positive disease, with interest in molecularly defined patient groups.
Immune Checkpoint Inhibition and Chemoimmunotherapy
Investigation centres on immune checkpoint inhibitors used alone or with chemotherapy in NSCLC, including maintenance and post-progression settings.
- Durvalumab
- Atezolizumab
- Cemiplimab
- Tislelizumab
These studies address overall survival, disease control, and treatment selection after prior chemoimmunotherapy.
Targeted Therapy for Molecular Subtypes
Research activity also covers targeted treatment in molecularly selected lung cancer, including alterations associated with resistance or specific oncogenic drivers.
- EGFR exon 20 insertion mutations
- MET amplification
- MET exon 14 skipping
- Bevacizumab-based combinations
These trials reflect interest in precision treatment options for patients with molecularly defined NSCLC who may not be suited to standard platinum-based therapy.
Maintenance and Biomarker-Driven Approaches
Additional work examines treatment decisions guided by circulating tumour DNA and maintenance strategies after initial chemoimmunotherapy.
- ctDNA clearance
- HLA-A2 positive NSCLC
- Docetaxel-based combinations
Research in this area focuses on identifying patients who may benefit from continued immune-based treatment in advanced non-small-cell lung cancer.
